SAN CARLOS, Calif., Nov 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host an R&D Day for investors and analysts at The Palace Hotel in New York, New York on Wednesday, November 14, 2007, beginning at 12:00 p.m. Eastern Time. The event will conclude at approximately 5:00 p.m.
Nektar's R&D Day will consist of a series of presentations by company executives, Nektar scientists and proprietary product program heads. The presentations will feature discussions on Nektar's industry-leading PEGylation and pulmonary technology platforms, the company's key research and development activities, and its clinical development pipeline.
The presentations and Q&A sessions will be accessible via a live audio and slideshow Webcast through a link on the Nektar website: http://www.nektar.com/wt/page/rd This Webcast will be available for replay until November 21, 2007.
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
Contact: Nektar Therapeutics, 650-631-3100, fax, 650-631-3150
SOURCE Nektar Therapeutics
http://www.nektar.com/
Copyright (C) 2007 PR Newswire. All rights reserved
News Provided by COMTEX